Browse our 650+ Publications
Latest Publications
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa L, et al.
Lancet Haematology
September 2023
Authors and Affiliates
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt, Kelly N Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D'Souza, Aric C Hall, Pamela Hardwick, James Omel, Robert F Cornell, Parameswaran Hari, Natalie S Callander
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Kubicki T, et al.
British Journal of Haematology
September 2023
Authors and Affiliates
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Jan Maciej Zaucha, Damian Mikulski, Olga Czabak, Oscar B Lahoud, Andrew Stefka, Benjamin A Derman, Andrzej J Jakubowiak.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, et al.
Haematologica
August 2023
Authors and Affiliates
Zachary D. Epstein-Peterson1 , Esther Drill2 , Umut Aypar3 , Connie Lee Batlevi1 , Philip Caron1 , Ahmet Dogan3 , Pamela Drullinsky1 , John Gerecitano1 , Paul A. Hamlin1 , Caleb Ho3 , Allison Jacob4 , Ashlee Joseph1 , Leana Laraque1 , Matthew J. Matasar1 , Alison J. Moskowitz1 , Craig H. Moskowitz1 , Chelsea Mullins4 , Colette Owens1 , Gilles Salles1 , Heiko Schöder5 , David J. Straus1 , Anas Younes1 , Andrew D. Zelenetz1 , and Anita Kumar1 1 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center 2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center 3Department of Pathology, Memorial Sloan Kettering Cancer Center 4Adaptive Biotechnologies, Seattle, WA, USA 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Vos JL, et al.
Nature Medicine
August 2023
Authors and Affiliates
Joris L Vos 1, Bharat Burman 2, Swati Jain 1, Conall W R Fitzgerald 1, Eric J Sherman 2, Lara A Dunn 2, James V Fetten 2, Loren S Michel 2, Anuja Kriplani 2, Kenneth K Ng 2, Juliana Eng 2, Vatche Tchekmedyian 3, Sofia Haque 4, Nora Katabi 5, Fengshen Kuo 1, Catherine Y Han 1, Zaineb Nadeem 1, Wei Yang 1, Vladimir Makarov 6, Raghvendra M Srivastava 6, Irina Ostrovnaya 7, Manu Prasad 1, Charlotte L Zuur 8,9, Nadeem Riaz 10, David G Pfister 2, Christopher A Klebanoff 2,11,12, Timothy A Chan 6, Alan L Ho 13, Luc G T Morris 14;
1 Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3 Department of Medicine, Maine Medical Center-Tufts University School of Medicine, Portland, ME, USA.
4 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 Center for Immunotherapy and Precision Immuno-oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
7 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8 Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
9 Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands.
10 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
11 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
12 Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
13 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hoa@mskcc.org.
14 Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors
Rudqvist N, et al.
Nature Communications
August 2023
Authors and Affiliates
Nils-Petter Rudqvist 1,2,3, Maud Charpentier 1, Claire Lhuillier 1,4, Erik Wennerberg 1,5, Sheila Spada 1, Caroline Sheridan 6, Xi Kathy Zhou 7, Tuo Zhang 8, Silvia C Formenti 1, Jennifer S Sims 9,10, Alicia Alonso 6, Sandra Demaria 11,12;
1 Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA.
2 Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson, Houston, TX, 77030, USA.
3 Department of Immunology, University of Texas MD Anderson, Houston, TX, 77030, USA.
4 Department of Immuno-Oncology, Sanofi, 94403, Vitry-sur-Seine, France.
5 Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SM2 5NG, UK.
6 Department of Medicine, Weill Cornell Medicine, New York, NY, 10065, USA.
7 Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, 10065, USA.
8 Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, 10065, USA.
9 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
10 Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
11 Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA. szd3005@med.cornell.edu.
12 Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, 10065, USA. szd3005@med.cornell.edu.
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
Tvingsholm SA, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Siri Amanda Tvingsholm 1, Marcus Svensson Frej 2, Vibeke Mindahl Rafa 1, Ulla Kring Hansen 2, Maria Ormhøj 1, Alexander Tyron 1, Agnete W P Jensen 3, Mohammad Kadivar 1, Amalie Kai Bentzen 1, Kamilla K Munk 1, Gitte N Aasbjerg 1, Jeppe S H Ternander 2, Christina Heeke 1, Tripti Tamhane 1, Christian Schmess 4, Samuel A Funt 5, Julie Westerlin Kjeldsen 3, Anders Handrup Kverneland 3, Özcan Met 6, Arianna Draghi 3, Søren Nyboe Jakobsen 1, Marco Donia 3, Inge Marie Svane 3, Sine Reker Hadrup 7;
1 Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
2 PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark.
3 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
4 NMI Natural and Medical Science Institute, University of Tübingen, Tubingen, Germany.
5 Deptartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
6 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Copenhagen, Denmark.
7 Department of Health Technology, Technical University of Denmark, Lyngby, Denmark sirha@dtu.dk.
T-cell tolerant fraction as a predictor of immune-related adverse events
Ostmeyer J, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Jared Ostmeyer 1, Jason Y Park 2, Mitchell S von Itzstein 3, David Hsiehchen 3,4, Farjana Fattah 4, Mary Gwin 3, Rodrigo Catalan 4, Shaheen Khan 2, Prithvi Raj 5, Edward K Wakeland 5, Yang Xie 1,4, David E Gerber 6,3,4;
1 Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
2 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
3 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
4 Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
5 Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
6 Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA David.Gerber@utsouthwestern.edu.
mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint TEMRA-like CD8+ T cells in COVID-19 recovered individuals
Mayer-Blackwell K, et al.
Cell Reports Medicine
August 2023
Authors and Affiliates
Koshlan Mayer-Blackwell 1, Heeju Ryu 1, Amy S Codd 1, K Rachael Parks 1, Hugh R MacMillan 1, Kristen W Cohen 1, Terri L Stewart 1, Aaron Seese 1, Maria P Lemos 1, Stephen C De Rosa 1, Julie L Czartoski 1, Zoe Moodie 1, Long T Nguyen 1, Donald J McGuire 2, Rafi Ahmed 2, Andrew Fiore-Gartland 1, M Juliana McElrath 3, Evan W Newell 4;
1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
2 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
3 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: jmcelrat@fredhutch.org.
4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: enewell@fredhutch.org.
Rigorous benchmarking of T-cell receptor repertoire profiling methods for cancer RNA sequencing
Peng K, et al.
Briefings in Bioinformatics
August 2023
Authors and Affiliates
Kerui Peng 1, Theodore S Nowicki 2,3, Katie Campbell 4, Mohammad Vahed 1, Dandan Peng 5, Yiting Meng 1, Anish Nagareddy 6, Yu-Ning Huang 1, Aaron Karlsberg 1, Zachary Miller 7, Jaqueline Brito 1, Brian Nadel 1,8, Victoria M Pak 9,10, Malak S Abedalthagafi 11,12, Amanda M Burkhardt 1, Houda Alachkar 1, Antoni Ribas 13, Serghei Mangul 1,5;
1 Department of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
2 Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, Los Angeles, CA, USA.
3 Department of Microbiology, Immunology, & Molecular Genetics, University of California, Los Angeles, CA, USA.
4 Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA, USA.
5 Department of Quantitative and Computational Biology, USC Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA.
6 Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA.
7 Department of Pharmaceutical Sciences, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
8 Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, CA, USA.
9 Emory Nell Hodgson School of Nursing, Emory University, Atlanta, GA, USA.
10 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
11 Department of Pathology & Laboratory Medicine, Emory University Hospital, Atlanta, GA, USA.
12 King Salman Center for Disability Research, Riyadh, Saudi Arabia.
13 Departments of Medicine (Hematology-Oncology), Surgery (Surgical Oncology) and Molecular & Medical Pharmacology, University of California, Los Angeles, CA, USA.